Many studies have tried to relate the occurrence of tumour TP53 mutations to drug activity with conflicting results (for reviews see Brown and Wouters, 1999; Gasco and Crook, 2003; Cimoli et al, 2004). The gene discussed is TP53; the disease is neoplasm.